Revenue from global prescription drug sales should increase 5 percent to 7 percent next year, reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.
The monoclonal antibody rituximab given in addition to a standard chemotherapy regimen of fludarabine plus cyclophosphamide significantly prolongs the lives of patients with chronic lymphocytic leukaemia compared with standard chemotherapy alone.
The data demonstrated that Jevtana with prednisone reduced the risk of death by 30% in men with metastatic castration-resistant prostate cancer whose disease progressed following treatment with a docetaxel-containing treatment regimen.
Amgen announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer, respectively.
ISTA Pharmaceuticals, Inc. announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies.
Researchers at Immunocore Limited announced that IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has received regulatory and ethics approval and has opened enrollment for clinical trials in the UK and USA.
NephRx Corporation announced that a study has shown that its peptide NX002 demonstrated significant efficacy when tested in an animal model of oral mucositis. Mucositis is a debilitating and often dose-limiting side effect of many forms of cancer therapy.
A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has discovered that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.
The Automation Partnership (TAP) has announced RAFT (Real Architecture for 3D Tissue), its system for generating reproducible, 3D collagen tissue constructs.
Combining research on factors affecting BME-dependent cell invasion assay performance with the advantages of offering the assay in a format where the BME is already coated on the invasion plate, the 96 well CultreCoat optimized BME cell invasion assay was designed.
Thermo Fisher Scientific Inc. has introduced the Piko and Arktik Thermal Cyclers. These two Thermo Fisher Scientific PCR instruments meet the needs of a broad range of researchers, for applications covering individual PCRs through to high throughput projects.
Two Fold Software’s easy-to-use Qualoupe LIMS solution has been tailored to support the requirements of commercial contract research laboratories.
A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin has been established with the objective of identifying and developing novel small molecule drugs against epigenetic factors.
Cisbio Bioassays, member of IBA Group and global provider of HTRF (homogenous time resolved fluorescence) technology and services to facilitate new drug discovery, announces the signing of a partnership with Blue Sky BioProducts.
Scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances.